Related Experiment Video
Updated: Jul 17, 2026
05:33
Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
Published on: July 11, 2025
Smartphone Applications in Dermatology With Special Focus on AI: A European-Continent-Based Review
Tobias Sangers1, Ahmad Naweed Shifai1,2, Davide Giovanni Jacob Pasqualini1,3
1Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
International Journal of Dermatology
|July 16, 2026
Summary
Dermatology apps are common in Europe but lack validation and regulatory compliance. Most apps, including AI-driven skin cancer tools, show poor adherence to standards, raising patient safety concerns.
Area of Science:
- Dermatology
- Medical Informatics
- Artificial Intelligence in Healthcare
Background:
- Smartphone applications for dermatology are prevalent across Europe.
- Limited evidence exists regarding their characteristics, validation, and regulatory compliance.
- The European Academy of Dermatology and Venereology (EADV) Artificial Intelligence (AI) Task Force initiated a review.
Purpose of the Study:
- To systematically review European dermatology apps available in app stores.
- To assess the characteristics, AI functionality, regulatory compliance (GDPR, CE marking), and scientific validation of these apps.
- To evaluate AI-based skin cancer screening apps specifically, including updates from 2026.
Main Methods:
- Systematic search of app stores in 44 European countries in 2024 and an updated search for AI skin cancer apps in June 2026.
- Categorization of apps by function and extraction of metadata (cost, target audience, AI presence, GDPR, CE marking).
- Assessment of scientific validation through linked publications, clinical trials, randomized controlled trials (RCTs), and real-world studies.
Main Results:
- 1746 apps identified in 2024, with 420 meeting inclusion criteria. 61% available on both major app stores; 94% were free; 60% targeted laypersons.
- 12% reported AI functionality in 2024, with 41% of those focused on skin cancer diagnosis. Only 2% had CE marking and 10% reported GDPR compliance.
- Scientific validation was limited: 20% linked to publications, 24 apps had clinical trials, 5 RCTs, 6 post-deployment studies. 38 AI skin cancer apps found in 2026. Adherence to EADV recommendations was poor (≤37% for key principles).
Conclusions:
- Major gaps exist in regulatory compliance, clinical evidence, and transparency for European dermatology apps.
- These shortcomings raise significant patient safety concerns regarding reliability and safety.
- There is a critical need for enhanced quality assurance, real-world validation, and inclusion of diverse skin types, aligning with EADV AI Task Force recommendations.
Related Concept Videos
01:29Issues And Trends In Healthcare Delivery System
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...